TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
The robust, high-quality data and clinical studies supporting the use of Abiomed's (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation. The conference will meet virtually and in-person in Orlando, Florida, on November 4 – 6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005297/en/
Impella CP with SmartAssist, shown placed in the heart’s left ventricle. (Photo: Business Wire)
Impella heart pumps are the world’s smallest heart pumps. They unload the heart while providing coronary and end organ perfusion. Impella SmartAssist technology enables improved patient outcomes via real-time intelligence. Abiomed augments limited hospital resources by providing 24x7 support on-site, on-call and online.
Throughout TCT, and at a pre-conference workshop on November 3, leading physician-researchers will present data demonstrating:
- Complete revascularization with Impella improves ejection fraction and long-term patient outcomes.
- Cardiogenic shock best practices, including early unloading with Impella pre-PCI and timely escalation to Impella RP and Impella 5.5 with SmartAssist, are associated with improved survival and native heart recovery.
During TCT 2021, physicians will detail final results from two large studies of Impella -- the PROTECT III post approval study and the RESTORE EF study. Interim results from both studies were presented at TCT 2020 and demonstrated the benefits of using contemporary practices to achieve complete revascularization with Impella.
The high-quality clinical evidence being generated from the PROTECT series of studies includes the PROTECT II randomized controlled trial (RCT) and the ongoing PROTECT IV RCT of Impella use in high-risk PCI patients. Based on PROTECT II RCT data, and data from additional robust prospective clinical studies, the United States Food and Drug Administration (FDA) granted Impella premarket approvals (PMA) as safe and effective for high-risk PCI, cardiogenic shock and right heart failure.
TCT presenters will also review the real-world evidence (RWE) and best practices gathered since Impella’s FDA approvals. This evidence will inform the RECOVER IV RCT of Impella use in cardiogenic shock patients. The RWE includes prospective data from the National Cardiogenic Shock Initiative (NCSI) Study, J-PVAD Study and INOVA Study. These datasets demonstrate cardiogenic shock best practices, including early use of Impella, are associated with improved survival rates of 71%, 77% and 82% (respectively), compared to the historical cardiogenic shock survival rate of about 50%.
In-person attendees of TCT 2021 are invited to visit Abiomed at the TCT Industry Hub, which will be open from 8:00 am – 5:30 pm EDT. At the Hub, attendees will be able to participate in hands-on Impella demonstrations, view the newest technologies, talk with members of the Abiomed product development team, and learn the latest information about Abiomed’s ongoing and planned randomized controlled trials.
Virtual attendees of TCT 2021 are invited to participate in three ways:
- Visit www.HeartRecovery.com 24x7 to experience Abiomed’s virtual cath lab and view live and on-demand TCT-related video content.
- Follow the @HeartRecovery and @ProtectedPCI Twitter handles for the latest TCT news and events.
- Tune in for the live TCT recap program, livestreamed on www.HeartRecovery.com at 6:00 pm EDT on Thursday, November 4, and Friday, November 5. Chuck Simonton, MD, and Seth Bilazarian, MD, from the Abiomed medical office will present the top TCT news of the day. After the live broadcast, the program will be available for on-demand viewing.
In-person and virtual participants of TCT are invited to attend a breakfast symposium on Thursday, November 4. The principal investigators of the PROTECT IV RCT, the RECOVER IV RCT and the STEMI Door-to-Unloading RCT will update the physician community on the progress of those trials. The symposium will also review the clinical experience with the new 9 French Impella ECP heart pump. The schedule of presentations and instructions for in-person and virtual viewing are below:
Clinical Science to Landmark Trials of Left Ventricular Unloading in High-Risk PCI and Cardiogenic Shock
Date: Thursday, November 4, 2021
Time: 6:30 – 7:30 am EDT
In-Person Location: Orange County Convention Center, Clinical Science Theater, Level 1, Halls A & B
Virtual Location: Watch via the official TCT 2021 conference livestream
Presenters:
- PROTECT Series Leading to PROTECT IV, Gregg Stone, MD, Mount Sinai Health System, New York City
- Real World Evidence Leading to RECOVER IV, William O’Neill, MD, Henry Ford Hospital, Detroit
- Door to Unload: Implications for STEMI, High-Risk PCI and Cardiogenic Shock, Navin Kapur, MD, Tufts Medical Center, Boston
- Breaking the Small-Bore Barrier: Impella ECP 9 Fr Heart Pump Clinical Experience, Amir Kaki, MD, Ascension St. John Hospital, Detroit
In conjunction with TCT, Abiomed is also hosting a pre-meeting workshop on November 3 for members of CAMP PCI. CAMP PCI (Coronary Artery & Myocardial Protected PCI) is the leading online and in-person physician education platform dedicated to improving patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005297/en/
Contact information
Media Contact:
Tom Langford
Director of Communications
+1 (978) 882-8408
tlangford@abiomed.com
Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ-GfK Wins Radio and TV Measurement Contracts in South Africa15.10.2025 12:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, is proud to announce that the Broadcast Research Council of South Africa (BRC) has appointed GfK, an NIQ company, to provide comprehensive measurement of radio and television audiences nationwide. This milestone marks a new era for South African media, marketing, and advertising, empowering the industry with robust, innovative, and actionable audience data. Following a rigorous and competitive selection process, the BRC first awarded the Radio Audience Measurement System (RAMS) contract to GfK in June 2025. The first round of radio data collection is already underway and initial insights will be released in Q1 2026. In addition, GfK will also design and deploy South Africa’s new Total Video Measurement service, aligning the country’s TV currency with the way audiences consume content today. Gary Whitaker, CEO of the BRC, commented, “We are pleased to partner with GfK and NIQ for the next chapter of audience measurement in South
Bentley Systems Advances Infrastructure AI with New Applications and Industry Collaboration15.10.2025 10:53:00 EEST | Press release
Bentley Systems’ Year in Infrastructure 2025 – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today unveiled new infrastructure AI capabilities at its Year in Infrastructure conference. Bentley also announced an Infrastructure AI co-innovation initiative, inviting engineering firms and asset owners to collaborate on the next generation of AI workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015714746/en/ Bentley's OpenSite+, the first engineering application leveraging generative AI for civil site design, is now in limited availability. It delivers projects up to 10 times faster without sacrificing accuracy. (Image courtesy of Bentley Systems) “AI is poised to transform infrastructure,” said Bentley CEO Nicholas Cumins. “At Bentley, our vision is for AI to empower infrastructure engineers—not replace them. Trustworthy AI, built on infrastructure context, can improve e
Bentley Systems Announces Bentley Infrastructure Cloud Connect15.10.2025 10:51:00 EEST | Press release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced Bentley Infrastructure Cloud Connect, the new foundational layer of Bentley Infrastructure Cloud. Connect provides a connected data environment and unified experience for infrastructure professionals interacting with project and asset data, improving collaboration across the infrastructure lifecycle and value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015261978/en/ Bentley Systems announced Bentley Infrastructure Cloud Connect, providing a trusted foundation to connect data and people across the infrastructure lifecycle and value chain. (Image courtesy of Bentley Systems) “Infrastructure data lives everywhere—in models, PDFs, inspection forms, photos, IoT sensors, and more—and it’s rarely connected,” said Julien Moutte, chief technology officer, Bentley S
Bentley Systems Bolsters Cesium with Reality Modeling Capabilities, Brings Geospatial Context to Infrastructure Engineering15.10.2025 10:50:00 EEST | Press release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. It also unveiled geospatial capabilities for project delivery and asset performance and a new immersive engagement application for infrastructure teams and stakeholders, all powered by Cesium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015286327/en/ Bentley announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. (Image courtesy of Bentley Systems) Since acquiring Cesium a year ago, Bentley has made significant progress in integrating technologies from both companies, powering its own products and empowering developers to build applications that visualize infrastru
SkySparc Acquires Inovotek Solutions to Strengthen Its Capital Markets Expertise and Expand Delivery Across Murex, Calypso, and FIS Platforms15.10.2025 10:00:00 EEST | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Inovotek Solutions (“Inovotek” or the “Company”), a specialist provider of transformation services to capital markets and financial institutions. Financial terms were not disclosed. The acquisition will bolster SkySparc's position as a premier provider of comprehensive digital transformation services to capital markets clients globally. It will address critical client challenges, including regulatory compliance and complex re-platforming initiatives. Additionally, SkySparc will expand its expertise across leading trading and risk management platforms such as Murex, Calypso, and FIS. By combining Inovotek’s program management expertise with SkySparc’s established managed services and proprietary software – OmniFi and Optimizer – the Company will deliver a robust and complete offering capable of addressing the most complex and demanding client
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom